Oppenheimer has downgraded LeMaitre Vascular (NASDAQ:LMAT) to perform from outperform as its price target of $93 has been met ...

Medical device company LeMaitre Vascular (NASDAQ:LMAT) in Q4 CY2024, but sales rose 14% year on year to $55.72 million. Next ...

Citizens JMP raised the firm’s price target on LeMaitre (LMAT) to $113 from $100 and keeps an Outperform rating on the shares. LeMaitre’s Q4 ...

Barrington analyst Michael Petusky downgraded LeMaitre (LMAT) to Market Perform from Outperform without a price target following the Q4 report.

Revenue was in line with analyst estimates. Earnings per share (EPS) was also in line with analyst expectations. Looking ...

LeMaitre Vascular Inc (LMAT) reports robust sales growth and strategic global expansion, while navigating regulatory and ...

Detailed price information for Integra Lifesciences (IART-Q) from The Globe and Mail including charting and trades.

This article was originally published on Quiver News, read the full story. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of ...

On Friday, Oppenheimer analysts downgraded LeMaitre Vascular (NASDAQ:LMAT) stock rating from Outperform to Perform. The decision came after the company’s fourth-quarter earnings report ...

For the current quarter ending in March, LeMaitre said it expects revenue in the range of $56.7 million to $58.7 million. The company expects full-year earnings to be $2.15 to $2.32 per share, with ...

Welcome to the LeMaitre Vascular Q4 2024 Financial Results Conference Call. As a reminder, today's conference is being recorded. At this time, I would like to turn the call over to Mr. J.J ...

BURLINGTON, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants, and services, reported Q4 2024 results ...